Declarations
Ethical approval: Ethical approval is not required as this is not a clinical trial.
Consent: Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.
Competing interests: The authors declare there are no conflicting interests.
Funding and sponsorship of this paper: Self-funding and no sponsorship received.
Author’s contribution: G.K. analysed the data, designed the paper and wrote the first draft of the manuscript. J.S. made critical revisions and approved the final manuscript.
Guarantor: Ganesh Kasinathan is the guarantor of this manuscript.
Acknowledgements: None
References
  1. Gupta S, Fenves A, Nance ST, et al. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion. 2015; 55(3):623-628
  2. Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev Hematol. 2009; 2(2):111-115.
  3. Win N. Blood transfusion therapy for hemoglobinopathies. In: Practical Management of Hemoglobinopathies. Okpala 1 (Ed). Blackwell Publishing. Oxford, UK. 2004; 99-106.
  4. Segel G, AL Marshall. Direct antiglobulin (Coombs) test-negative autoimmune hemolytic anemia: A review. Blood cells Mol and Dis. 2014; 52(4):152-60.
  5. Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014; 54(2):384-388.
  6. Petz LD, Garratty G. Bystander immune hemolysis immune hemolytic anemias (2nd edition). Churchill Livingstone, PA, USA. 2004; 358-364.
  7. Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion. 1997; 37:357-361.
  8. Morawakage LR, Perera BJ, Dias PD, et al. Hyperhemolysis in a patient with beta-thalassemia major. Asian J Transfus Sci. 2009; 3(1):26-27
  9. Reid ME, Lomas-Francis C. The blood group antigen: facts book. The blood group system and antigen. San Diego: Academic Press. 2014; 111-112.
  10. May-Wewres J, Kaiser JR, Moore EK, et al. Severe neonatal analysis due to maternal antibody to low frequen cy Rh antigen Cw. Am J Perinatol. 2006; 23:213-217.
  11. Trial J, rice L. Erythropoietin withdrawal leads to destruction of young red cells at the endothelial-macrophage interface. Curr. Pharmaceut. Design. 2004; 10(2):183-190.
  12. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfusion Med. Rev. 2007; 21:S9-S56.
  13. Bachmeyer C, Maury J, parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol. 2010; 85:91-2.
  14. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016; 127(8):1062-1064.
  15. Mechery J, Abidogun K, Crosfill F, et al. Hyperhemolysis syndrome complicating pregnancy in homozygous deltabeta thalassemia. Hemoglobin. 2012; 36(2):183-185.